Influenza vaccine manufacture: keeping up with change

Journal of Infectious Diseases

Volumn 200, Issue 6, 2009, Pages 835-837

  Neuzil, Kathleen M ^a,b,c   Bright, Rick A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Departments of Medicine and Global Health

^c PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; UNITED STATES; VACCINE PRODUCTION; VIRUS STRAIN; ANTIGENIC VARIATION; CLASSIFICATION; DRUG INDUSTRY; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A;

ANTIGENIC VARIATION; DISEASE OUTBREAKS; DRUG INDUSTRY; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 70349435478     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605507     Document Type: Note

References (12)

1. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):l-60.
2. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children. Arch Pediatr Adolesc Med 2004; 158:1031-1036
3. 3. Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the U.S. experience. Expert Rev Vaccines 2008; 7:75-82. (Pubitemid 351359054)
4. Izurieta HS, Haber P, Wise RP, et al. Early postmarketing surveillance of the first live, coldadapted, intranasal influenza vaccine in the U.S. JAMA 2005; 294:2720-2725
5. Neuzil KM, Griffin MR. Vaccine safety: achieving the proper balance. JAMA 2005; 294:2763-2765
6. World Health Organization. Recommendations for influenza vaccine composition: Northern Hemisphere: 2005-2006. Available at: http://www.who.int/ csr/disease/influenza/ vaccinerecommendations1/en/index4.html. Accessed 6 June 2009.
7. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swineorigin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197-201.
8. Katz J, Hancock K, Vegiulla V, et al. Serum cross-reactive antibody response to a novel influenza a (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521-524
9. Wright PF. Vaccine preparedness-are we ready for the next influenza pandemic? N Engl J Med 2008; 358:2540-2543
10. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-848 (in this issue).
11. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-857 (in this issue).
12. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirusexpressed hemagglutinin influenza vaccine. JAMA 2007; 297:1577-1582